Drug data last refreshed 31m ago · AI intelligence enriched 2w ago
INFED (iron dextran) is an intravenous iron replacement therapy approved in 1974 for treating iron deficiency anemia in patients who cannot tolerate oral iron supplementation. It is a small-molecule iron-carbohydrate complex administered via injection to rapidly replenish iron stores.
With LOE approaching and moderate competitive pressure (30), the brand team is likely consolidating around cost-containment and retention strategies rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
Working on INFED offers limited career growth due to its LOE-approaching lifecycle and zero linked job openings; career value lies primarily in managed care negotiation, cost optimization, and patient retention expertise. This is a defensive, cost-management role rather than a launch or growth opportunity.
Worked on INFED at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo